

FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2008

FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2008				
(Rs. in Lakhs)				
Sr. No	Particulars	Quarter ended 30.06.2008 (Unaudited)	Quarter ended 30.06.2007 (Audited)	Year ended 31.03.2008 (Audited)
1.	Net Sales/Income from operations	22,118	22,740	87,693
2.	Other Income	1,628	419	5,228
	Total Income	23,746	23,159	92,921
3.	Total Expenditure (a+b+c+d+e+f)	17,712	16,848	65,113
	a. (Increase)/decrease in stock in trade and work in progress	(713)	(1,669)	(1,196)
	b. Consumption of Raw Materials	10,529	10,825	37,425
	c. Purchase of traded Goods	933	612	2,913
	d. Power cost	1,871	2,043	7,612
	e. Employee cost	2,015	1,947	6,957
	f. Other Expenditure	3,077	3,090	11,402
4.	Profit before Interest, Depreciation & Taxes (1+2-3)	6,034	6,311	27,808
5.	Interest and finance charges	182	89	288
6.	Depreciation & amortisation	1,768	1,670	6,900
7.	Profit Before Taxation and exceptional items (4-5-6)	4,084	4,552	20,620
8.	Provision for current tax (including fringe benefit tax)	315	151	1,057
9.	Provision for deferred tax	(102)	(85)	7
10.	Net Profit (7-8-9) before exceptional items	3,871	4,486	19,556
11.	Exceptional Items (Net of tax) - [See note 3 below]	(870)	-	23,937
12.	Net Profit	3,001	4,486	43,493
13.	Paid-up equity share capital (Par value Rs.5)	5,000	5,000	5,000
14.	Reserves excluding revaluation reserves			127,725
15.	Earnings per share before Exceptional Items			
	Basic - (in Rs.)	4.01	4.64	20.25
	Diluted - (in Rs.)	3.89	4.50	19.64
16.	Earnings per share after Exceptional Items			
	Basic - (in Rs.)	3.10	4.64	45.02
	Diluted - (in Rs.)	3.01	4.50	43.67
17.	Aggregate of Public Shareholding			
	- Number of Shares	39,088,512	39,884,842	39,096,427
	- Percentage of shareholding	39.09%	39.88%	39.09%

SEGMENT REPORTING FOR THE QUARTER ENDED JUNE 30, 2008				
(Rs. in Lakhs)				
Sr. No	Particulars	Quarter ended 30.06.2008 (Unaudited)	Quarter ended 30.06.2007 (Audited)	Year ended 31.03.2008 (Audited)
1.	Segment revenue			
	a. Enzymes - Discontinued operations	-	2,527	4,773
	b. Pharma	22,118	20,340	83,122
	Total	22,118	22,867	87,895
	Less: Inter-segment revenue	-	127	202
	Net sales/Income from operations	22,118	22,740	87,693
2.	Segment results			
	Profit before interest, depreciation and tax from each segment			
	a. Enzymes - Discontinued operations	-	662	1,185
	b. Pharma	8,052	8,457	32,352
	Total	8,052	9,119	33,537
	Less: Interest	182	89	288
	Depreciation	1,768	1,670	6,900
	Unallocated corporate expenses	3,646	3,227	10,957
	Unallocable income	(1,628)	(419)	(5,228)
	Profit before tax excluding exceptional items	4,084	4,552	20,620
3.	Capital employed (Assets less Liabilities)			
	a. Enzymes - Discontinued operations	-	4,994	-
	b. Pharma	84,795	88,796	88,806
	c. Unallocable	51,207	5,108	44,014
	Total capital employed	136,002	98,898	132,820

CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2008				
(Rs. in Lakhs)				
Sr. No	Particulars	Quarter ended 30.06.2008 (Unaudited)	Quarter ended 30.06.2007 (Audited)	Year ended 31.03.2008 (Audited)
1.	Net Sales/ Income from operations	26,393	27,083	105,379
2.	Other Income	1,260	138	3,641
	Total Income	27,653	27,221	109,020
3.	Total Expenditure (a+b+c+d+e+f)	20,635	19,435	75,519
	a. (Increase)/decrease in stock in trade and work in progress	(909)	(1,899)	(1,487)
	b. Consumption of Raw Materials	11,631	12,227	42,734
	c. Purchase of Traded Goods	933	612	2,257
	d. Power cost	1,885	2,051	7,656
	e. Employee cost	3,395	2,975	11,261
	f. Other Expenditure	3,700	3,469	13,098
4.	Profit before Interest, Depreciation & Taxes (1+2-3)	7,018	7,786	33,501
5.	Interest and finance charges	368	275	1,018
6.	Depreciation & amortisation	2,526	2,204	9,392
7.	Profit Before Taxation and Exceptional items (4-5-6)	4,124	5,307	23,091
8.	Provision for current tax (including fringe benefit tax)	328	404	1,122
9.	Provision for deferred tax	(155)	(256)	167
10.	Net Profit before minority interest (7-8-9)	3,951	5,159	21,802
11.	Add: Minority interest	100	141	652
12.	Net Profit before Exceptional items (10 + 11)	4,051	5,300	22,454
13.	Exceptional Items, (Net of tax) [See Note 3 below]	(2,549)	-	23,937
14.	Net Profit	1,502	5,300	46,391
15.	Paid-up equity share capital (Par value Rs.5)	5,000	5,000	5,000
16.	Reserves excluding revaluation reserves			143,320
17.	Earnings per share before exceptional items			
	Basic - (in Rs.)	4.19	5.49	23.25
	Diluted - (in Rs.)	4.07	5.32	22.55
18.	Earnings per share after exceptional items			
	Basic - (in Rs.)	1.55	5.49	48.03
	Diluted - (in Rs.)	1.51	5.32	46.58
19.	Aggregate of Public Shareholding			
	- Number of Shares	39,088,512	39,884,842	39,096,427
	- Percentage of shareholding	39.09%	39.88%	39.09%

Notes:

- The above results have been reviewed by the Audit Committee on July 16, 2008 and approved by the Board of Directors of the Company at their meeting held on July 17, 2008. The financial results of the Company and the consolidated financial results for the quarter ended June 30, 2008 have been subjected to a limited review by the statutory auditors of the Company.
- Effective April 30, 2008, Biocon acquired 71% equity interest in AxiCorp GmbH, Germany through its new incorporated wholly owned subsidiary company, Biocon SA, Switzerland. The financial statements of AxiCorp are drawn upto March 31, 2008 for the purposes of consolidation. Accordingly, the consolidated results of Biocon for the quarter ended June 30, 2008 do not include the results of AxiCorp. In accordance with AS 21, adjustments are made for the effects of significant transactions or events, between March 31, 2008 and June 30, 2008. The financial statements of other subsidiaries and joint venture companies have been drawn up to the same reporting dates as that of Biocon, i.e. June 30, 2008.
- Exceptional items:
 - Exceptional items for the quarter ended June 30, 2008 comprise of mark to market loss in respect of foreign exchange forward contracts, of Rs. 870 (net of taxes of Rs. 160) of the Company and Rs. 2,549 (net of taxes of Rs. 160) in respect of the consolidated financial results.
 - Effective October 1, 2007, the Company transferred its enzymes business to a third party and recorded a gain of Rs. 25,390 (net of taxes of Rs. 7,587).

- In December 2007, the Company recorded an impairment of Rs. 1,544 (net of tax of Rs. 656) in respect of one of its intellectual property which was in development stage.
- Profit before taxes of the Company and the Group include Rs. nil, Rs. 259 and Rs. 388, from the operating activities of the enzymes business for each of the aforesaid periods respectively.
- Profit after taxes of the Company and the Group include Rs. nil, Rs. 185 and Rs. 283, from the operating activities of the enzymes business for each of the aforesaid periods respectively.
- The primary segment reporting has been performed on the basis of business segments. Segments have been identified and reported based on the nature of the products, risks and returns, organizational structure and internal financial reporting systems.
- Total number of shareholder complaints pending at the beginning of the period were nil. 45 complaints were received during the period. All complaints have been resolved as at June 30, 2008.
- The prior period/year figures have been reclassified wherever required to conform to the classification of the current quarter.

For and on behalf of the Board of Directors

Sd/-
Kiran Mazumdar-Shaw
Chairman & Managing Director

Place: Bangalore Date: July 17, 2008